Chief Business Officer
Andrew Gengos joined Cyteir in February of 2020 as Chief Business Officer. Andrew brings to Cyteir more than 25 years of broad and extensive biopharmaceutical industry experience in strategic, operational, and financial roles at both emerging and established biopharmaceutical companies. Prior to joining Cyteir, Andrew served as the CFO and CBO of AOBiome, a private-stage microbiome therapeutics company. Andrew has held a range of senior business roles at several emerging biotech companies including COO of Synlogic, CEO of ImmunoCellular Therapeutics, CEO of Neuraltus Pharmaceuticals, and CFO and CBO of Dynavax Technologies. For more than seven years, Andrew served as Vice President of Strategy and Corporate Development at Amgen, managing all business development activities and closing multiple billions of dollars of M&A, licensing, and corporate venture capital transactions. He also led the execution of strategic projects and supported the long-range planning process for the company. Prior to Amgen, Andrew was Vice President of Strategy and Corporate Development at Chiron Corporation (now Novartis) and Senior Engagement Manager at McKinsey & Company focusing in their healthcare practice. Andrew earned his MBA from the UCLA Anderson School of Management and a BS in chemical engineering from the Massachusetts Institute of Technology.